PYXS PYXIS ONCOLOGY INC

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida.

A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, .

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-201 is designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors.

To learn more, visit  or follow us on  (formerly known as Twitter) and .

Pyxis Oncology Contact

Pamela Connealy

CFO and COO



EN
03/03/2025

Underlying

PYXSPYXIS ONCOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PYXIS ONCOLOGY INC

 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Res...

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) - Received Fast Track Designation from the U.S. Food and Drug Administration for MICVO for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemothe...

March 18, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology to Participate at the Leerink Partners Global Healthcar...

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida. A live webcast and replay of the fireside chat will be available on the Events & Presentations page i...

March 3, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monother...

Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that the U.S. Food a...

February 26, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates C...

Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 monotherapy trial expanded to include cohorts in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) - Ongoing commitment to innovative cancer therapies for patients with limited treatment options BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ...

February 4, 2025 1 EN
 PRESS RELEASE
Free
PYXS PYXIS ONCOLOGY ...

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources ...

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors - Current cash runway expected to fund development into 2H 2026 BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therape...

December 19, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch